Trinity Biotech Announces Results of AGM

DUBLIN, Ireland, Sept. 30, 2022 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a number one developer and producer of diagnostic merchandise for the point-of-care and scientific laboratory markets, immediately introduced the outcomes of an Annual General Meeting (AGM).

AGM Results

On September 30, 2022 Trinity Biotech plc held an AGM of Shareholders on the Company’s headquarters at IDA Business Park, Bray, Co. Wicklow, Ireland.

At the AGM, the Company’s shareholders authorised the next resolutions, as extra absolutely set out within the Notice of AGM dated September 8, 2022:

1. An strange decision to extend the Company’s authorised share capital by the creation of an extra 600,000,000 A strange shares of US$0.0109 every.
2. An strange decision to authorise the board of administrators to reappoint Grant Thornton because the Company’s statutory auditors.
3. An strange decision to authorise the board of administrators to repair the statutory auditors’ remuneration.
4. Re-election of administrators:
   1. An strange decision to re-elect as a director Mr. Aris Kekedjian who retires by rotation and, being eligible, gives himself for re-election.
   2. An strange decision to re-elect as a director Mr. Michael Sung Soo Kim who retires by rotation and, being eligible, gives himself for re-election.
   3. An strange decision to re-elect as a director Mr. Seon Kyu Jeon who retires by rotation and, being eligible, gives himself for re-election.
5. An strange decision to evaluate the affairs of the Company and contemplate the monetary statements of the Company for the 12 months ended December 31, 2021 along with the studies of the administrators and statutory auditors thereon.
6. A particular decision to change the Memorandum of Association of the Company.
7. A particular decision to undertake new Articles of Association of the Company to take account of sure modifications to Irish firm regulation ensuing from the Companies Act 2014 (the “Act”) and sure associated developments.
8. A particular decision to resume the authority for the Company and/or any of its subsidiaries to buy the Company’s personal shares and American Depositary Receipts evidencing such shares (“ADRs”) on NASDAQ inside sure prescribed limits.

Resolution 9, which sought to resume the value vary at which any shares or ADRs held in treasury (“Treasury Shares”) may be re-allotted apart from on a securities trade was not authorised by the requisite majority of shareholders.

While a majority of proxy votes obtained on Resolution 9 had been in favour of the decision, an inadequate quantity of votes in favour of Resolution 9 had been obtained with the intention to go it as a particular decision.

Trinity Biotech develops, acquires, manufactures and markets diagnostic programs, together with each reagents and instrumentation, for the point-of-care and scientific laboratory segments of the diagnostic market. The merchandise are used to detect infectious illnesses and to quantify the extent of Haemoglobin A1c and different chemistry parameters in serum, plasma and entire blood. Trinity Biotech sells direct within the United States, Germany, France and the U.Ok. and thru a community of worldwide distributors and strategic companions in over 75 international locations worldwide. For additional info, please see the Company’s web site: www.trinitybiotech.com.